Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Western world.

Early detection of HCC has been crucial in improving the survival outcomes of patients with metabolic dysfunction-associated steatohepatitis (MASH), even in the absence of cirrhosis. Understanding how hepatocarcinogenesis develops in MASH is increasingly becoming a …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is estimated to affect 25-30% of the population worldwide. MASLD encompasses a spectrum of liver disease from hepatic steatosis, steatohepatitis, to cirrhosis.

Oct 1, 2024 · HCC in MASLD occurs on non-cirrhotic livers in one-third of cases. HCC in MASLD without cirrhosis is most often discovered incidentally, and thus at more advanced stages. Survival in patients with MASLD and HCC depends on …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality.

Jan 6, 2024 · Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Weste …

We delve into MASH-HCC-associated genetic variations and somatic mutations, disease progression and research models, multiomics analysis, immunological and microenvironmental impacts, and discuss targeted/combined therapies to overcome immune evasion and the biomarkers to recognize treatment responders.

Jan 6, 2024 · MASLD-HCC is now the fastest rising cause of HCC and the fastest growing indication for orthoptic liver transplantation (from 2.1% to 16.2% from 2000 to 2016) . Dynamic Markov modelling for MASLD-HCC across eight countries …

Apr 9, 2024 · Phenotyping MASLD-HCC would contribute to optimizing the identification of MASLD subjects with a greater risk of HCC, refine screening strategies in noncirrhotic populations, design personalized therapeutic approaches for MASLD, and individualize the systemic therapy in MASLD-HCC.

Mar 6, 2025 · The incidence of HCC estimated to be 3.8 per 100 person-years in individuals with MASLD-related cirrhosis and 0.03 per 100 person-years among people with non-cirrhotic MASLD 52.